defect is not important for the elimination of alfentanil, since the drug is not metabolized by the human cytochrome P-450 form that catalyzes debrisoquine 4-hydroxylation. This is further substantiated by in vivo findings described in two recent publications, which show that the metabolism of alfentanil in poor metabolizers of debrisoquine was not deficient.

Finally, we wish to emphasize that, in order to draw valid conclusions, extrapolations from in vitro to in vivo should be based on a thorough investigation and characterization of the in vitro system.

KAREL L. M. LAVRIJSEN, PH.D.
Group Leader

JOSEPH J. P. HEYKANTS, PH.D.
Director

Department of Drug Metabolism and Pharmacokinetics
Janssen Research Foundation
B-2340 Beerse
Belgium

In Reply—Drs. Lavrijsen and Heykants, using their recent data\textsuperscript{2} make a valid analysis as to an extended interpretation of our data.\textsuperscript{1} They point out that the $K_i$ of alfentanil being nearly eightfold higher than the $K_m$,\textsuperscript{4} represents additional evidence of the unimportance of debrisoquin hydroxylase in the metabolism of alfentanil. We agree that this is a valuable argument that deserves to be raised.

The letter also correctly points out that we ignored this relationship by deliberately confining ourselves to studying only inhibition. By restricting our investigation to inhibition, we were able to screen nine opioid analogues. It is a matter of opinion whether this widely used technique, meant only to screen for presence of in vitro competitive inhibition, actually overemphasizes competitive inhibition. Such a study\textsuperscript{1} can “be used as screening tests to identify drugs that interact with the debrisoquin hydroxylase,” that in vivo studies performed in response to these results “found alfentanil clearance to be unaffected by the debrisoquin hydroxylase,” and that the “importance of this polymorphism to the metabolism of fentanyl and dextropropoxyphene deserves investigation.” These conclusions\textsuperscript{1} are conservative and completely consistent with the use for which this test was originally designed.\textsuperscript{3}

For these reasons we agree with the concluding two paragraphs of the letter, outlining further investigations about the metabolism of alfentanil and amplifying the necessity of a complete characterization of the in vitro metabolic system before extrapolating to in vivo circumstances.

REFERENCES


(Received for publication May 18, 1989.)

THOMAS K. HENTHORN, M.D.
Assistant Professor of Anesthesiology
Northwestern University Medical School
303 E. Chicago Avenue
Chicago, Illinois 60611

REFERENCES


(Accepted for publication May 18, 1989.)